DERM (Journey Medical) Land And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Land And Improvements?

Journey Medical's land and improvements for the quarter that ended in Mar. 2025 was $0.00 Mil.

Journey Medical Land And Improvements Historical Data

The historical data trend for Journey Medical's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical Land And Improvements Chart

Journey Medical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

Journey Medical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Journey Medical Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Journey Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258

Website

https://www.journeymedicalcorp.com

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Executives

Joseph Benesch	officer: Interim CFO	C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
Claude Maraoui	director, officer: President & CEO	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Justin Adam Smith	director	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Jeffrey Paley	director	C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
De Paolantonio Ernest Robert	officer: Chief Financial Officer	4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135